Acadia Pharmaceuticals (ACAD) said late Tuesday it has struck a deal to sell its rare pediatric disease priority review voucher for $150 million.
Acadia said it was granted the voucher in March 2023 following approval from the US Food and Drug Administration of DAYBUE to treat Rett syndrome.
Acadia initially licensed DAYBUE from Neuren Pharmaceuticals in August 2018, and is required to pay Neuren a third of the net proceeds.
The company said it plans to invest the proceeds in commercial operations, research and development programs in the central nervous system and rare diseases, and in future business development.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。